Trial Profile

Multi-centre, Open-label, Expanded Access Trial of Spesolimab i.v. in Patients With Generalized Pustular Psoriasis (GPP) Presenting With a Flare

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Spesolimab (Primary)
Indications Generalised pustular psoriasis
Focus Adverse reactions; Expanded access; Registrational
Sponsors Boehringer Ingelheim

Most Recent Events

24 Mar 2023 Status changed from active, no longer recruiting to completed.
20 Mar 2023 Planned End Date changed from 13 Mar 2023 to 20 Mar 2023.
20 Mar 2023 Planned primary completion date changed from 13 Mar 2023 to 20 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com